2 news items
Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
SEEL
19 Mar 24
-tolerated and comparable to placebo in safety. There was an imbalance of deaths/death equivalents observed in the study, with more events seen in the SLS-005
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
SEEL
19 Mar 24
-hoc analyses. SLS-005 was generally well-tolerated and comparable to placebo in safety. There was an imbalance of deaths/death equivalents observed
- Prev
- 1
- Next